STERIS (STE) Q4 2026 earnings review
Steady Top-Line Growth Masking Cash Flow and Margin Pressures
STERIS delivered a solid finish to FY26 with Q4 revenue growing 7% to $1.59B, driven by resilient procedure volumes and recurring service revenue. However, underlying profitability growth is decelerating. Adjusted Net Income grew just 3% in Q4 (compared to 15% growth earlier in the year), as management explicitly cited tariffs and inflation eating into volume and pricing gains. While FY27 guidance calls for a healthy 9-11% bump in Adjusted EPS and the Board approved a new $1 billion share buyback, the cash flow narrative is reversing: Free Cash Flow is guided to shrink from $983M in FY26 to $850M in FY27, partially burdened by a new $60M U.S. manufacturing facility.
🐂 Bull Case
Service revenues remain highly robust across all segments (Healthcare +9%, AST +10%, Life Sciences +8% in Q4), acting as a highly predictable utility-like utility engine that insulates the company from capital spending cycles.
After a prolonged trough in FY25, Life Sciences capital equipment sales surged 19% in Q4, signaling that pharma and biotech customers are unlocking budgets and driving facility expansions.
🐻 Bear Case
Applied Sterilization Technologies (AST) capital equipment plummeted 62% in Q4. If this capital digestion phase drags on, it threatens the high-margin growth of the segment.
FY27 Free Cash Flow is guided down to $850M from $983M in FY26, breaking a multi-year trend of robust cash generation, driven by working capital normalizations and capital outlays.
⚖️ Verdict: ⚪
Neutral. Operations are highly stable and the core service business is thriving, but shrinking free cash flow and a sharp slowdown in AST capital equipment temper the excitement. The $1B buyback is a strong floor for the stock.
Key Themes
Healthcare Services Provide a Bedrock
The Healthcare segment remains the company's anchor, growing 7% organically in Q4. The 9% growth in service and 7% in consumables reflects an unyielding demand for procedural volume support and sterilization capacity at hospitals. This stable recurring revenue stream allows the company to absorb shocks in the capital cycle.
Life Sciences Exit Trough
Life Sciences is accelerating out of its FY25 slump. The segment delivered 9% reported growth in Q4, supercharged by a 19% leap in capital equipment. This aligns with prior management commentary regarding rebounding pharma capital spending and the onshoring of aseptic manufacturing capacity.
AST Capital Equipment Plunges
In a sharp trend break, Applied Sterilization Technologies (AST) capital equipment revenue collapsed 62% YoY in Q4. While the core services business within AST remained strong at 10% growth, the capital shock dragged total segment constant currency organic growth down to a sluggish 2%. This represents a stark deceleration from the 103% capital equipment surge seen in Q3.
Tariffs and Inflation Cap Margins
Despite achieving volume and price improvements in Q4, management explicitly noted that these gains were 'significantly offset by tariffs and inflation' in both the Healthcare and Life Sciences segments. The tariff headwind, heavily cited throughout FY26 (peaking at an expected $55M run rate), continues to be a structural drag preventing meaningful operating leverage.
U.S. Manufacturing Consolidation
STERIS is investing $60 million over the next two years to build a state-of-the-art sterility assurance manufacturing plant in Mentor, Ohio. This will consolidate existing U.S. production into a single center of excellence, a strategic move likely aimed at defending against global supply chain fragility and localized tariff exposures.
Other KPIs
Accelerating from $787.2 million in FY25. The nearly $200M jump was primarily driven by improved net income. However, management is guiding for a sharp reversal in FY27 down to $850 million.
The Board approved a new $1 billion share repurchase program to replace the prior authorization. With gross debt to EBITDA running historically low (around 1.2x as of Q3), STERIS has the balance sheet flexibility to aggressively defend its share price or offset dilution.
Guidance
Stable. The constant currency organic growth is projected at 6-7%, perfectly in line with the company's long-term operational targets, showing resilience against macroeconomic noise.
Accelerating. The midpoint of $11.20 implies a 10.1% YoY growth over FY26's $10.17. This represents a distinct acceleration from the sluggish 3.3% Adjusted EPS growth realized in Q4 FY26, suggesting management expects cost/tariff pressures to be more effectively mitigated.
Reversing. A significant step down from the $982.9 million achieved in FY26. While CapEx is roughly flat YoY at ~$375M, the working capital benefits that massively boosted FY26 cash flows are likely unwinding.
Key Questions
AST Capital Equipment Collapse
AST capital equipment dropped 62% YoY in Q4 after surging over 100% in Q3. Is this strictly a matter of order timing and tough comps, or has a major customer digestion phase begun in the medtech space?
Bridging the Free Cash Flow Gap
Free Cash Flow is guided to drop by roughly $133 million in FY27 despite expectations for double-digit earnings growth and flat Capital Expenditures. Can you walk through the specific working capital dynamics driving this reversal?
Margin Offset Timelines
You noted that tariffs and inflation significantly offset volume and price gains in Q4. Given the 9-11% Adjusted EPS growth guidance for FY27, when do you expect pricing and the new Mentor, Ohio consolidation to outpace these inflationary headwinds?